| 1 |
Carter ZJ, Hollander K, Spasov KA, Anderson KS, Jorgensen WL. Design, synthesis, and biological testing of biphenylmethyloxazole inhibitors targeting HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2023;84:129216. [PMID: 36871704 DOI: 10.1016/j.bmcl.2023.129216] [Reference Citation Analysis]
|
| 2 |
Zhao L, Pannecouque C, De Clercq E, Wang S, Chen F. Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety. Chinese Chemical Letters 2023. [DOI: 10.1016/j.cclet.2023.108261] [Reference Citation Analysis]
|
| 3 |
Prener L, Baszczyňski O, Kaiser MM, Dračínský M, Stepan G, Lee YJ, Brumshtein B, Yu H, Jansa P, Lansdon EB, Janeba Z. Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties. J Med Chem 2023;66:1761-77. [PMID: 36652602 DOI: 10.1021/acs.jmedchem.2c01574] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Ling X, Hao QQ, Huang WJ, Pannecouque C, De Clercq E, Wang S, Chen FE. Development of novel S-N(3)-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity. Eur J Med Chem 2023;247:115042. [PMID: 36577220 DOI: 10.1016/j.ejmech.2022.115042] [Reference Citation Analysis]
|
| 5 |
Zhou RL, Ju Z, Pannecouque C, Clercq E, Wang S, Chen FE. Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs. Eur J Med Chem 2023;246:114939. [PMID: 36442370 DOI: 10.1016/j.ejmech.2022.114939] [Reference Citation Analysis]
|
| 6 |
Zhang H, Liu C, Zhu D, Zhang Q, Li J. Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners. J Med Chem 2023;66:1-31. [PMID: 36583662 DOI: 10.1021/acs.jmedchem.2c01016] [Reference Citation Analysis]
|
| 7 |
Sun Y, Zhou Z, Feng D, Jing L, Zhao F, Wang Z, Zhang T, Lin H, Song H, De Clercq E, Pannecouque C, Zhan P, Liu X, Kang D. Lead Optimization and Avoidance of Metabolic-perturbing Motif Developing Novel Diarylpyrimidines as Potent HIV-1 NNRTIs. J Med Chem 2022;65:15608-26. [PMID: 36411036 DOI: 10.1021/acs.jmedchem.2c00576] [Reference Citation Analysis]
|
| 8 |
Wang S, Ren Y, Wang Z, Jiang X, Xu S, Zhang X, Zhao S, Zalloum WA, Liu X, Zhan P. The current progress in the use of boron as a platform for novel antiviral drug design. Expert Opin Drug Discov 2022;17:1329-40. [PMID: 36448326 DOI: 10.1080/17460441.2023.2153829] [Reference Citation Analysis]
|
| 9 |
Zuo Y, Li R, Zhang Y, Bao G, Le Y, Yan L. Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors. J Enzyme Inhib Med Chem 2022;37:2742-54. [PMID: 36176072 DOI: 10.1080/14756366.2022.2128797] [Reference Citation Analysis]
|
| 10 |
Xu S, Sun L, Zalloum WA, Huang T, Zhang X, Ding D, Shao X, Jiang X, Zhao F, Cocklin S, De Clercq E, Pannecouque C, Dick A, Liu X, Zhan P. Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators. Molecules 2022;27. [PMID: 36500508 DOI: 10.3390/molecules27238415] [Reference Citation Analysis]
|
| 11 |
Zhang X, Sun L, Xu S, Shao X, Li Z, Ding D, Jiang X, Zhao S, Cocklin S, Clercq E, Pannecouque C, Dick A, Liu X, Zhan P. Design, Synthesis, and Mechanistic Study of 2-Pyridone-Bearing Phenylalanine Derivatives as Novel HIV Capsid Modulators. Molecules 2022;27. [PMID: 36364467 DOI: 10.3390/molecules27217640] [Reference Citation Analysis]
|
| 12 |
Kang D, Yang J, Kong L, Luo R, Huang X, Zhang T, Ma M, Feng D, Wang Z, Fang H, Zhan P, Zheng Y, Liu X. Structure-Based Discovery and Characterization of a Preclinical Drug Candidate for the Treatment of HIV-1 Infection. Viruses 2022;14. [PMID: 36366488 DOI: 10.3390/v14112390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Ling X, Hao Q, Pannecouque C, Clercq ED, Chen F. Expansion of the S–CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry 2022;238:114512. [DOI: 10.1016/j.ejmech.2022.114512] [Reference Citation Analysis]
|
| 14 |
Benedetto Tiz D, Bagnoli L, Rosati O, Marini F, Sancineto L, Santi C. New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use. Molecules 2022;27:1643. [PMID: 35268744 DOI: 10.3390/molecules27051643] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
